Skip to main content Skip to footer
Investor Relations
Back to OpusGTX.com
Opus Genetics, Inc. IR Overview
  • Overview
  • Press Releases
  • Events
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • Back to OpusGTX.com

Press Releases

Aug 7, 2019 6:30 am EDT
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development
Jul 22, 2019 8:00 am EDT
Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
rss_feed News RSS
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
©2025 Opus Genetics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement